Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001609351-19-000067
Filing Date
2019-07-22
Accepted
2019-07-22 16:19:10
Documents
5
Period of Report
2018-12-31
Effectiveness Date
2019-07-22

Document Format Files

Seq Description Document Type Size
1 DEF 14A a2019proxystatementform.htm DEF 14A 1015513
2 proxycardfinal002page1.jpg GRAPHIC 227886
3 proxycardfinal002page2.jpg GRAPHIC 262479
4 sparklogoa03.jpg GRAPHIC 81426
5 sparkproxy3a02.jpg GRAPHIC 20261
  Complete submission text file 0001609351-19-000067.txt   1826427
Mailing Address 3737 MARKET STREET SUITE 1300 PHILADELPHIA PA 19104
Business Address 3737 MARKET STREET SUITE 1300 PHILADELPHIA PA 19104 888-772-7560
Spark Therapeutics, Inc. (Filer) CIK: 0001609351 (see all company filings)

EIN.: 462654405 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36819 | Film No.: 19965838
SIC: 2836 Biological Products, (No Diagnostic Substances)